Clinical trials: Attention-Deficit and Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder
Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
The objective of this study was to establish that an optimal dose of Quillivant XR oral suspension would result in a significant reduction in signs and symptoms of ADHD compared to placebo treatment in pediatric patients ages…
- Trial name
- NCT00904670
- Testing
- Quillivant Oral Suspension XR
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder
L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults
This pilot study seeks to evaluate initial evidence for the effect of L-methylfolate supplementation to OROS-Methylphenidate pharmacotherapy on ADHD symptoms and associated features in adults with ADHD, as well as tolerability of…
- Trial name
- NCT01853280
- Testing
- L-methylfolate, OROS-Methylphenidate
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Massachusetts General Hospital
Huntington Disease, Chorea
Citalopram to Enhance Cognition in HD
This research plan proposes to conduct a double-blind, placebo-controlled pilot clinical trial in 36 adults with mild Huntington's disease (HD) to address the following research aims: 1.
- Conditions
- Huntington Disease, Chorea, Executive Dysfunction
- Trial name
- CIT-HD (NCT00271596)
- Testing
- 20mg daily citalopram
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Iowa
ADHD
Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS
The primary objective of the study is to assess the efficacy and tolerability of a 12-week trial of memantine hydrochloride administered twice daily in 20 adults (ages 18-55) with ADHD and ADHD NOS.
- Trial name
- NCT00586573
- Testing
- memantine hydrochloride
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder
Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder
The purpose of this study is to determine the long-term efficacy and safety of KAPVAY™ (clonidine hydrochloride) extended-release in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
- Trial name
- NCT01439126
- Testing
- clonidine hydrochloride
- Volunteers
- 135 people
- Sponsor
- Concordia Pharmaceuticals Inc., Barbados
Attention-Deficit/Hyperactivity Disorder
Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 in adult ADHD patients
- Trial name
- NCT04143217
- Testing
- SPN-812
- Where
- 38 sites in United States
- Volunteers
- 159 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Oppositional Defiant Disorder, Conduct Disorder
Integrated Smart Speaker Promoting Positive Parenting Among Caregivers of Youth With Challenging Behaviors
This project will develop and evaluate the feasibility of an integrated smart speaker and mobile/web-based application, "FamilyNet" (FN) to assist parents in implementing empirically supported behavioral parenting strategies to…
- Trial name
- FamilyNet (NCT05535387)
- Testing
- FamilyNet smart speaker/mobile application
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Insomnia, Attention Deficit Hyperactivity Disorder
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
- Trial name
- NCT00857220
- Testing
- eszopiclone
- Where
- 89 sites in United States
- Volunteers
- 304 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Hyperactivity Disorder
Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder
The purpose of this study is to assess the efficacy, the quality of life, and the safety of multiple dosing atomoxetine in Asian adult subjects with attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT00962104
- Testing
- Atomoxetine
- Where
- 24 sites in Japan, South Korea and 1 more
- Volunteers
- 391 people
- Sponsor
- Eli Lilly and Company
ADHD
Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD
- Trial name
- NCT00501293
- Testing
- Methylphenidate Transdermal System
- Where
- 32 sites in United States
- Volunteers
- 163 people
- Sponsor
- Noven Therapeutics
Attention Deficit Disorder With Hyperactivity
Neuroimaging of the Effects of Concerta in the Treatment of ADHD
A number of brain regions have been down to be altered in both structure and function in patients with ADHD, including prefrontal cortex, anterior cingulate, caudate and cerebellum.
- Trial name
- NCT00778310
- Testing
- methylphenidate-OROS
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
ADHD, Oppositional Defiant Disorder
Remote School-Home Program to Improve Youth Attention and Behavior in Mexican Students
Neurodevelopmental disorders of inattention and disruptive behavior, such as Attention-Deficit/ Hyperactivity Disorder (ADHD) and Oppositional Defiant Disorder (ODD), are among the most common youth mental health conditions…
- Trial name
- NCT05496140
- Testing
- CLS-R-FUERTE
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- University of California, San Francisco
ADHD, Substance Use Disorders
Integrated Treatment for Adolescents With ADHD
Attention-Deficit/Hyperactivity Disorder (ADHD) exists in 20-50% of the 3 million adolescents annually enrolled in outpatient mental health and substance use treatment.
- Trial name
- CASALEAP IT2A (NCT02420990)
- Testing
- Medication Integration Protocol (MIP), Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA)
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- The National Center on Addiction and Substance Abuse at Columbia University
Attention Deficit/Hyperactivity Disorder(ADHD)
Effect of Vyvanse on Driving in Young Adults With ADHD
The primary objective of the study is to assess the benefice of Vyvanse on the factors that cause impairments in driving behavior in individuals with ADHD using a driving simulation aimed at examining the factors that cause…
- Trial name
- NCT00801229
- Testing
- Vyvanse
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder
Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children
Purpose of the study: evaluate the efficacy and safety of Prospekta in the treatment of attention deficit/hyperactivity disorder in children.
- Trial name
- NCT04569357
- Testing
- Prospekta
- Where
- 31 sites in Russia
- Volunteers
- 363 people
- Sponsor
- Materia Medica Holding
ADHD, Attention Deficit Hyperactivity Disorder
Brain Plasticity Underlying Acquisition of New Organizational Skills in Children
Organizational, time management and planning (OTMP) skills deficits are impairing features of developmental disorders, such as Attention Deficit Hyperactive Disorder (ADHD), which compromise school performance and family…
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, Neurodevelopmental Disorders
- Trial name
- NCT04108273
- Testing
- Organizational Skills Training
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- NYU Langone Health
ADHD
A Novel, Non-pharmacological, Intervention for the Management of ADHD in Adolescents
This is a 2-month study in which eligible ADHD adolescents will be provided with personalized VIZO Glasses
- Trial name
- NCT05835336
- Testing
- VIZO Glasses
- Where
- Israel
- Volunteers
- 32 people
- Sponsor
- VIZO Specs Ltd
Attention-Deficit/Hyperactivity Disorder (ADHD)
Evaluation of Immediate-Release Viloxazine in Adults With ADHD
This will be a randomized, double-blind, placebo-controlled, parallel group, safety and tolerability study in adults with ADHD. The target subjects are healthy male or female adults aged 18 to 64 years, inclusive, with a…
- Trial name
- NCT01107496
- Testing
- IR Viloxazine
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
While the Lisdexamfetamine Dimesylate (SPD489) clinical program has studied the efficacy, safety, and tolerability of SPD489 in treating core symptoms of ADHD in children and adolescents aged 6-17 years and adults aged 18-55…
- Trial name
- NCT01328756
- Testing
- Lisdexamfetamine dimesylate
- Where
- 35 sites in Belgium, Germany and 8 more
- Volunteers
- 314 people
- Sponsor
- Shire
Attention-Deficit/Hyperactivity Disorder
Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder
The primary objective of this study is to evaluate the maintenance of efficacy, as measured by Adult ADHD Rating Scale with Prompts (Adult ADHD-RS with prompts) and Clinical Global Impression - Severity (CGI-S) scores, through a…
- Trial name
- NCT00877487
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 55 sites in United States
- Volunteers
- 123 people
- Sponsor
- Shire